SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 467.88 |
| Enterprise Value ($M) | 378.22 |
| Book Value ($M) | 258.28 |
| Book Value / Share | 3.75 |
| Price / Book | 1.81 |
| NCAV ($M) | 139.50 |
| NCAV / Share | 2.03 |
| Price / NCAV | 3.35 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.38 |
| Return on Assets (ROA) | -0.32 |
| Return on Equity (ROE) | -0.48 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.08 |
| Current Ratio | 5.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 279.59 |
| Assets | 398.37 |
| Liabilities | 140.09 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 20.76 |
| Operating Income | -139.03 |
| Net Income | -132.49 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -106.84 |
| Cash from Investing | 158.35 |
| Cash from Financing | 45.49 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | State Street Corp | 10.43 | ||
| 13G/A | Wasatch Advisors Inc | |||
| 13G/A | Lynx1 Capital Management LP | 6.40 | 0.39 | |
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 5.20 | -12.54 | |
| 13G | Soleus Capital Master Fund, L.P. | 5.20 | 39.22 | |
| 13G | Betta Investment (Hong Kong) Ltd. | 8.10 | ||
| 13G | Point72 Asset Management, L.P. | 5.40 | ||
| 13G | Ra Capital Management, L.p. | 9.90 | ||
| 13G | Commodore Capital Lp | 7.70 | ||
| 13G | Millennium Management Llc | 4.80 | ||
| 13G/A | BlackRock Inc. | 4.30 | -42.38 | |
| 13G/A | ArrowMark Colorado Holdings LLC | 3.04 | -74.26 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 349,219 | 460,840 | 75.78 | |
| 308,393 | 573,122 | 53.81 | |
| 497,794 | 775,459 | 64.19 | |
| 150,110 | 327,425 | 45.85 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BOLT – Bolt Biotherapeutics, Inc. | BPMC – Blueprint Medicines Corporation |
| CABA – Cabaletta Bio, Inc. | CGC – Canopy Growth Corporation |
| CGEM – Cullinan Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io